Heterocyclic-substituted tricyclics of the formula ##STR1##

or a pharmaceutically acceptable salts thereof, wherein:

• n₁ and n₂ are independently 0-2;
• Het is an optionally substituted mono-, bi- or tricyclic heteroaromatic group;
• B is alkyl or optionally substituted alkenyl;
• R²² is —COR²³ or a carboxy, sulfinyl, sulfonyl, sulfonamide or amino acid derivative;
• R²³ is haloalkyl; alkenyl; haloalkenyl; alkynyl; optionally substituted cycloalkyl; cycloalkyl-alkyl; aryl; arylalkyl; heteroaryl; heterocycloalkyl; or —COOH and/or —SO₃H substituted alkyl;
• R¹, R², R³, R⁹, R¹⁰ and R¹¹ are as defined in the specification;

  are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds.